Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Kinjel Shah headshot

3 Large Drug Stocks That Have Outperformed Industry YTD

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce

Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Accenture & The TJX Companies

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).

Novo Nordisk (NVO) to Expand Manufacturing Site in France

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.

Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

ABBV vs. LLY: Which Stock Should Value Investors Buy Now?

ABBV vs. LLY: Which Stock Is the Better Value Option?

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

Style Box ETF report for PWB

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Sector ETF report for IYH

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sanghamitra Saha headshot

Billionaires Bullish on Big Tech: ETFs in Focus

The latest 13-F filings of billionaires indicate that most are still bullish on big techs.

Andrew Rocco headshot

13F Rundown: Tepper, Buffett, Druckenmiller

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

Smart Beta ETF report for GSEW

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

Style Box ETF report for QUS

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

Smart Beta ETF report for FTCS

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.

Novo Nordisk's (NVO) Wegovy Positive in Cardiovascular Study

Novo Nordisk's (NVO) obesity drug Wegovy shows potential in cardiovascular study beyond the benefits of associated weight loss.

Kinjel Shah headshot

4 Large Drug Stocks Likely to Sail Through Industry Woes

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.